Characterization of Cefiderocol Heteroresistance in Carbapenem-Resistant Acinetobacter Baumannii (CRAB) Following Exposure to Human Pleural Fluid (HPF)
Open accessPreprint — published as 10.3390/ijms241411752
Abstract
Objectives: Carbapenem-resistant Acinetobacter baumannii (CRAB) isolates are one of the most difficult pathogens to treat. Cefiderocol, a chlorocatechol-substituted siderophore antibiotic, was approved by the U.S. Food and Drug Administration (FDA) in 2019 indicated for the treatment of infections due to CRAB infections. Despite the initial positive treatment outcomes with this antimicrobial, recent studies reported higher than all-cause mortality rate in patients treated with cefiderocol. The cause(s) behind these outcomes remains unconfirmed. A plausible hypothesis is heteroresistance, a phenotype characterized by the survival of a small proportion of cells in a population seemingly isogenic. Recent results have shown that the addition of human fluids to CRAB cultures leads to cefiderocol heteroresistance. Here we describe molecular and phenotypic analyses of CRAB heteroresistant bacterial subpopulations to better understand the nature of the less-than-expected successful outcomes after cefiderocol treatment. Methods: Isolation of heteroresistant variants of the CRAB strain AMA40 was carried out in cultures supplemented with cefiderocol and human pleural fluid (HPF). Two AMA40 variants, AMA40 IHC1 and IHC2, were subjected to whole genome sequencing and transcriptional analysis to identify mutations and expression changes associated with cefiderocol heteroresistance. The impact of these mutations on the pharmacodynamic activity of cefiderocol was assessed via susceptibility testing, EDTA and boronic acid inhibition analysis, biofilm formation, and static time-kill assays. Results: Heteroresistant variants AMA40 IHC1 and AMA40 IHC2 have 53 chromosomal mutations, of which 40 are common to both strains. None of the mutations occurred in genes associated with high affinity iron-uptake systems or β-lactam resistance. However, transcriptional analyses showed significant modifications in levels of expression of genes associated with these functions. The blaNDM-1 and blaADC-2, as well as various iron-uptake system genes, were expressed at higher levels than the parental strain. On the other hand, the carO and ompA genes’ expression was reduced. One of the mutations common to both heteroresistant strains mapped within pipA, a gene associated with iron homeostasis in other species. Static time-kill assays showed that supplementing cation-adjusted Mueller-Hinton broth with human serum albumin, the main protein component of HPF, considerably reduced cefiderocol killing activity for all three strains tested. Notably, collateral resistance to amikacin was observed in both variants. Conclusions: We conclude that exposing CRAB to fluids containing high HSA facilitates the rise of heteroresistance associated with point mutations and upregulation of genes coding for β-lactamases and biofilm formation.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Time-kill assays can detect heteroresistance by identifying delayed growth or survival of heteroresistant subpopulations undetected by static MIC assays.
“By measuring the rate of cell death at various time points, this method can identify delayed growth or survival of heteroresistant subpopulations undetected by static MIC assays, and even evaluate the kinetics of heteroresistance and assess whether heteroresistant cells eventually adapt to drug pressure, which makes for wide clinical applicability [172,173,174].”
From Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance (2025) · cites this paper as [172]
The “Static time-kill studies” section describes measuring bacterial counts over time in two already identified heteroresistant strains, and the susceptibility-results section reports reduced cefiderocol killing against them. The paper does not show that time-kill assays detected subpopulations missed by MIC assays, or establish delayed growth, eventual adaptation, or wide clinical applicability. Page numbers are unavailable in our copy. (LLM, conf=0.83)
Experimental — accuracy not yet measuredTime-kill assays can evaluate kinetics of heteroresistance and assess whether heteroresistant cells eventually adapt to drug pressure.
“By measuring the rate of cell death at various time points, this method can identify delayed growth or survival of heteroresistant subpopulations undetected by static MIC assays, and even evaluate the kinetics of heteroresistance and assess whether heteroresistant cells eventually adapt to drug pressure, which makes for wide clinical applicability [172,173,174].”
From Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance (2025) · cites this paper as [172]
The Static time-kill studies section (page unavailable) says the assays measured bacterial killing kinetics over eight hours in the parental strain and two heteroresistant derivatives. The paper reports reduced cefiderocol killing against the derivatives, but does not use these assays to assess whether heteroresistant cells eventually adapt to drug pressure. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 69 · Cited by 27
Research works printed but not linked: 4
- M. Bassetti, R. Echols, Y. Matsunaga, M. Ariyasu, Y. Doi, R. Ferrer, T.P. Lodise, T. Naas, Y. Niki, D.L. Pater- son, S. Portsmouth, J. Torre-Cisneros, K. Toyoizumi, R.G. Wunderink, T.D. Nagata, Efficacy and safety of Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 June 2023 doi:10.20944/preprints202306.0950.v1 cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, de- scriptive, phase 3 trial, Lancet Infect Dis 21(2) (2021) 226-240.
- T.O. Jacob E. Choby, Carter N. Abbott, Sarah W. Satola, David S. Weiss, Heteroresistance via beta-lactamase gene amplification threatens the beta-lactam pipeline, bioRxiv 2021.05.19.444899 (2022).
- Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 June 2023 doi:10.20944/preprints202306.0950.v1
- C.L.S.I. (CLSI), Performance standards for antimicrobial susceptibility testing: Thirty Edition informational supplement. CLSI Document M100-S30:2020, Clinical Lab Standards Institute (2020).
- Authors
- Mezcord, V., Escalante, J., Nishimura, B., Traglia, G. M., Sharma, R., Valle, Q., Tuttobene, M. R., Subils, T., Marin, I., Pasterán, F., Actis, L. A., Tolmasky, M. E., Bonomo, R. A., Rao, G. G., & Ramírez, M. S.
- Affiliations
- California State University, Fullerton (US)
- Universidad de la República de Uruguay (UY)
- University of North Carolina at Chapel Hill (US)
- Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
- Administración Nacional de Laboratorios e Institutos de Salud (AR)
- Miami University (US)
- Louis Stokes Cleveland VA Medical Center (US)
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-06-13
- Volume
- 24
- Issue
- 14
- Pages
- 11752-11752
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10380697
- OpenAlex
- W4385161816
- Cited by
- 27
- References
- 69
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 8 · 2023: 1
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repositorio Hipermedial UNR (Universidad Nacional de Rosario) (submittedVersion, cc-by)
- Funders
- U.S. Department of Veterans Affairs (1I01BX001974)
- Office of Research and Development (1I01BX001974, VISN 10)
- Wockhardt
- National Institutes of Health (R01AI100560, R01AI063517, R01AI072219, R01AI100560, R01AI063517)
- Geriatric Research Education and Clinical Center (VISN 10))
- National Institute of General Medical Sciences (SC3GM125556)
- National Institute of Allergy and Infectious Diseases (R01AI063517, R15AI047115, R01AI100560, R01AI072219)
- NIH Clinical Center (R01AI100560, R01AI063517, R01AI072219)
- National Institute on Minority Health and Health Disparities (P031C160152, MHRT 2T37MD001368, 1I01BX001974, T37MD001368)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- carbapenem-resistant Acinetobacter baumannii, cefiderocol, heteroresistance, iron uptake systems, iron acquisition, NDM-1, ADC(2), Caro, OmpA, siderophore biosynthesis, biofilm formation, time-kill kinetics
- MeSH terms
- Cefiderocol, Acinetobacter Infections, Anti-Bacterial Agents, beta-Lactamases, Humans, Iron, Microbial Sensitivity Tests, Carbapenems, Acinetobacter baumannii
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review